Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

HLS Therapeutics Inc T.HLS

Alternate Symbol(s):  HLTRF

HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. The Vascepa (icosapent ethyl capsules) is a single-molecule prescription product in use to reduce the risk of cardiovascular events.


TSX:HLS - Post by User

Bullboard Posts
Comment by LTOWNERon Apr 24, 2012 7:19am
219 Views
Post# 19827404

RE: BNS Selling

RE: BNS Selling

The explanation I received was that Scotia held a large number of shares for several years, much more so than they generally do.  The turnaround in AM's  revenues and earnings plus the special dividends created the liquidity for Scotia to take profits.  They did so initially in a very responsible way, around the $2.70 level.  In short, they began selling because they could.

 

The X-CEO took his profits less responsibly, knocking the share price down just after extremely strong 2011 results were released and the annual dividend was raised.  Go figure!

 

Only 900 insider shares sold yesterday.  We can only hope they are finally finished selling and a strong Q1 puts some legs back into the stock price.  Of couse the overall markets are not helping.  Some analysts see the correction continuing and say we could see a further 20% decline.  AM's yield and fundamentals may help short term.

Bullboard Posts